The consolidated, preliminary financial data of the “Grindeks” group show that the group closed 2021 with a record turnover and profit. During this period, the turnover of the “Grindeks” group reached 231.1 million euros, which is 44 million euros or 24% more than in 2020, the company reports. In 2021, the Group’s profit was 41 million euros, which is 22.1 million euros or twice as much as in 2020.
In 2021, the largest sales were medicines for the treatment of cardiovascular and central nervous system diseases. Medicines in the hospital segment, offered by “Grindeks” subsidiary “Kalceks”, also achieved rapid growth in sales. In 2021, the Group exported its products to 103 countries for a total amount of 218.7 million euros. Last year, the Group’s sales of finished medicines reached 219.5 million euros and, compared to 2020, have increased by 45.9 million euros or 26%. Last year, sales of finished medicines in the European Union and other countries reached 117.5 million euros, which is 31.6 million euros or 37% more than in 2020.
The product range of “Grindeks” includes modern medicines for the treatment of cardiovascular, central nervous system, oncological diseases and diabetes, while the subsidiary “Kalceks” offers medicines for the hospital segment. Currently, 64 new “Grindeks” and 42 “Kalceks” medicines are under development. In 2021, the drug registration procedure was initiated for 10 generic medicines.
Calclex has also launched decentralized procedures for the registration of nine new generic medicines in the European Union, including the registration of the first four antibiotic products for the hospital segment. Taking into account the company’s long experience in the development, production and registration of sterile dosage forms, the development of the first ophthalmic products has been started.
Currently, “Grindeks” produces 25 active pharmaceutical ingredients. This segment increases the independence of raw material manufacturers, so the company develops 36 new active pharmaceutical ingredients. The largest exports of “Grindeks” active pharmaceutical ingredients are to the countries of the European Union, Japan, the USA and Australia.
According to the representatives of the group, in 2021 “Kalceks” achieved excellent results. Sales grew rapidly, increasing both the number of exporting countries and expanding the product range with seven new generic medicines. At the end of 2021, the portfolio consisted of 35 medicines. In 2021, Kalceks products were sold in the amount of 66.7 million euros, which is 26.0 million euros or 64% more than in 2020. In 2021, Kalceks medicines were exported to 77 countries, the main ones being the Netherlands, Mexico, Great Britain, the Czech Republic and Poland.
In 2021, “Grindeks” paid special attention to the improvement of the production infrastructure and installation of new production equipment, including the modernization of the Laboratory of Finished Pharmaceutical Forms. “Grindeks Innovation Center” will be built in several stages in Riga, Asotes Street 12. In 2021, a design contract was signed and landscaping works were performed. The innovation center will provide complex production processes for active pharmaceutical ingredients, modern technological equipment and automated and energy-efficient solutions. It will be the largest pharmaceutical innovation center in the Baltic region, the company is convinced.
Infographics with detailed data on the group’s results: https://infogram.com/grindeks-koncerns-2021-gada-sasniedz-rekordlielu-apgrozijumu-un-pelnu-1hdw2jpkky1mp2l?live
–
